OBJECTIVE: To analyze the clinical characteristics and laboratory data, treatment and prognosis of @entity6582 vera (PV) and provide evidence for screening of high-risk population and looking for measures to reduce complecations. METHODS: A retrospective study was performed among 70 @entity1 with PV from May 2005 to May 2014, 43 males and 27 females, aged (56.6    13.1) to collect the data about characteristics, laboratory data, myelogram chromosome, karyotypes, @entity1864 and @entity4016 @entity4017 genes, as well as @entity880 dehydrogenase (LDH) and so on. RESULTS: At diagnosis, there were 42 cases (60.00%) had symptoms, 25 cases (35.71%) had @entity715 and @entity887 . @entity548 occurred in 3 cases (4.29%), @entity381 in 48 cases (68.57%), @entity382 in 7 cases (10.00%). The average hemoglobin at diagnosis was 195.17 g/L, the white blood cells count was 10.12 * 10(9)/L, the platelet count was 295 * 10(9)//L. The chromosome karyotypes were all normal. The positive percentage of @entity4016 @entity4017 mutation was 87.69% (57/65). The disease outcomes were @entity4018 for 3 paitents, @entity204 from ineffective treatment after transforming to @entity4018 and then biphenotype acute @entity1778 for 1 @entity1 , and @entity204 from @entity177 for 2 @entity1 . The level of @entity1307 in @entity4016 @entity4017 mutated group were significantly lower than those in wild-type @entity4016 @entity4017 group (P < 0.05). The level of hemoglobin and platelet counts in @entity4016 @entity4017 mutated group were significantly higher than those in wild-type @entity4016 @entity4017 group (both P < 0.05). CONCLUSION: PV is one of meyloproliferation @entity5 , characterized by abnormally increasing blood cells, @entity715 and transforming to other @entity5 .

[Clinical analysis of 70 cases of XXXX vera].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity6582 :: ('MESH:D011086', 'Disease') :: ['polycythemia'] @entity548 :: ('MESH:D006470', 'Disease') :: ['Hemorrhage'] @entity5 :: ('MESH:D009369', 'Disease') :: ['myeloproliferative neoplasms', 'neoplasm'] @entity1307 :: ('2056', 'Gene') :: ['erythropoietin'] @entity4016 :: ('3717', 'Gene') :: ['JAK2'] @entity177 :: ('MESH:D051437', 'Disease') :: ['cardiorespiratory failure'] @entity887 :: ('MESH:D004617', 'Disease') :: ['embolism'] @entity4018 :: ('MESH:D055728', 'Disease') :: ['myelofibrosis'] @entity381 :: ('MESH:D013163', 'Disease') :: ['splenomegaly'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity382 :: ('MESH:D006529', 'Disease') :: ['hepatomegaly'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis'] @entity1864 :: ('25;613', 'Gene') :: ['BCR/ABL'] @entity4017 :: ('p|SUB|V|617|F', 'ProteinMutation') :: ['V617F'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity6582 :: (MESH:D011086,Disease) :: ['polycythemia']
